Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.68 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19876264 | 0.81 | BTK (1.00) | BTK | |
| SCHEMBL19876246 | 0.80 | BTK (0.68) | BTKBRD4 | |
| SCHEMBL19876271 | 0.80 | BTK (0.57) | BTK | |
| SCHEMBL19876232 | 0.79 | BTK (0.67) | BTKBRD4SLC22A12 | |
| SCHEMBL19876259 | 0.74 | BTK (0.70) | BTKBRD4 | |
| SCHEMBL19876266 | 0.71 | BTK (0.56) | BTKBRD4 | |
| SCHEMBL19876208 | 0.70 | BTK (0.54) | BTK | |
| SCHEMBL19876181 | 0.70 | BTK (0.59) | BTKBRD4BRAF | |
| SCHEMBL19876284 | 0.68 | BTK (0.62) | BTK | |
| SCHEMBL19876240 | 0.66 | BTK (0.47) | BTKBRD4BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500569-B1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-05-18 | — | — | EP | disclosed |
| EP-3500569-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2019-06-26 | — | — | EP | disclosed |
| US-10266528-B2 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-20180051024-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-22 | — | — | US | disclosed |
| WO-2018035080-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266528-B2 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | BTK, SYK, LCK | BTK 1/4885BRD4 85/4885SLC22A12 4688/4885 |
| US-20180051024-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | BTK 1/4885BRD4 85/4885SLC22A12 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.